J G Brecht

Summary

Affiliation: InForMed GmbH-Outcomes Research and Health Economics
Country: Germany

Publications

  1. ncbi Pharmacoeconomic analysis of osteoporosis treatment with risedronate
    J G Brecht
    InForMed GmbH Outcomes Research and Health Economics, Schwanthaler Str 28, 85049 Ingolstadt, Germany
    Int J Clin Pharmacol Res 23:93-105. 2003
  2. ncbi Health-economic comparison of three recommended drugs for the treatment of osteoporosis
    J G Brecht
    InForMed Outcomes Research and Health Economics, Ingolstadt, Germany
    Int J Clin Pharmacol Res 24:1-10. 2004
  3. ncbi The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study
    P K Schädlich
    InForMed Gesellschaft für interdisziplinäre Forschung und Beratung im Gesundheitswesen mbH, Hamburg, Germany
    Pharmacoeconomics 13:719-30. 1998
  4. ncbi Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance
    P K Schädlich
    InForMed Gesellschaft für interdisziplinäre Forschung und Beratung im Gesundheitswesen mbH, Hamburg, Germany
    Pharmacoeconomics 14:653-69. 1998
  5. ncbi Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance
    P K Schädlich
    InForMed GmbH Outcomes Research and Health Economics, Ingolstadt, Germany
    Pharmacoeconomics 19:497-512. 2001
  6. ncbi [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]
    P K Schädlich
    InForMed GmbH Outcomes Research and Health Economics, Büro Itzehoe, Conrad Röntgen Str 58C, 25524 Itzehoe, Germany
    Z Rheumatol 63:59-75. 2004

Collaborators

Detail Information

Publications6

  1. ncbi Pharmacoeconomic analysis of osteoporosis treatment with risedronate
    J G Brecht
    InForMed GmbH Outcomes Research and Health Economics, Schwanthaler Str 28, 85049 Ingolstadt, Germany
    Int J Clin Pharmacol Res 23:93-105. 2003
    ..Based on this analysis, risedronate is a cost-effective treatment for postmenopausal osteoporosis within the German health care system, offering benefits for osteoporotic patients and for budget decision-makers...
  2. ncbi Health-economic comparison of three recommended drugs for the treatment of osteoporosis
    J G Brecht
    InForMed Outcomes Research and Health Economics, Ingolstadt, Germany
    Int J Clin Pharmacol Res 24:1-10. 2004
    ..This cost-effectiveness analysis gives evidence that bisphosphonates are cost effective. Under consideration of current prices and the published clinical evidence, risedronate dominates the comparison of DVO-recommended drugs...
  3. ncbi The cost effectiveness of acamprosate in the treatment of alcoholism in Germany. Economic evaluation of the Prevention of Relapse with Acamprosate in the Management of Alcoholism (PRAMA) Study
    P K Schädlich
    InForMed Gesellschaft für interdisziplinäre Forschung und Beratung im Gesundheitswesen mbH, Hamburg, Germany
    Pharmacoeconomics 13:719-30. 1998
    ..Based on the naturalistic design of the underlying clinical trial and on this economic evaluation, it can be concluded that adjuvant acamprosate therapy leads to net savings under 'real world' conditions...
  4. ncbi Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance
    P K Schädlich
    InForMed Gesellschaft für interdisziplinäre Forschung und Beratung im Gesundheitswesen mbH, Hamburg, Germany
    Pharmacoeconomics 14:653-69. 1998
    ..In the AIRE trial, the addition of ramipril significantly lowered rates of total mortality and rehospitalisation due to heart failure...
  5. ncbi Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance
    P K Schädlich
    InForMed GmbH Outcomes Research and Health Economics, Ingolstadt, Germany
    Pharmacoeconomics 19:497-512. 2001
    ..In the Ramipril Efficacy In Nephropathy (REIN) trial, ramipril significantly lowered the rate of reaching the combined end-point of doubling of baseline serum creatinine levels or end-stage renal failure (ESRF)...
  6. ncbi [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany]
    P K Schädlich
    InForMed GmbH Outcomes Research and Health Economics, Büro Itzehoe, Conrad Röntgen Str 58C, 25524 Itzehoe, Germany
    Z Rheumatol 63:59-75. 2004
    ..This was caused by cost savings in other sectors of the health care system due to the higher effectiveness of the sequences comprising LEF...